Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.

Keun-Wook LeeEric Van CutsemYung-Jue BangCharles S FuchsIveta KudabaMarcelo Garrido Hyun Cheol ChungJeeyun LeeHugo R CastroJoseph ChaoZev A WainbergZ Alexander CaoDeepti Aurora-GargJulie KobieRazvan CristescuPooja BhagiaSukrut ShahJosep Tabernero Kohei Shitara Lucjan Wyrwicz

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

This exploratory analysis of KEYNOTE-062 suggests an association between TMB and clinical efficacy with first-line pembrolizumab-based therapy in patients with advanced gastric/gastroesophageal junction adenocarcinoma. However, after the exclusion of patients with MSI-H tumors, the clinical utility of TMB was attenuated.

Keyphrases

phase iii
phase ii
open label
clinical trial
locally advanced
advanced non small cell lung cancer
squamous cell carcinoma
double blind
placebo controlled
randomized controlled trial
risk factors
stem cells
mesenchymal stem cells
study protocol
rectal cancer
replacement therapy
chemotherapy induced